VAUGHAN, Ontario / Sep 08, 2025 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of ASANA gas permeable (GP) lenses. ASANA offers eye care professionals a versatile, all-in-one comprehensive GP portfolio, featuring spherical, aspheric, toric, multifocal, multifocal toric, reverse geometry and keratoconic contact lenses.
“Many still prefer rigid gas permeable contact lenses for clear, comfortable and consistent vision,” said Yang Yang, president, Global Vision Care, Bausch + Lomb. “ASANA offers eye care professionals a catalog of customizable GP lenses designed to fit each patient’s unique corneal curves, ensuring a fantastic fit and sharp vision. These GP lenses also complete our custom Specialty Vision Products lens portfolio, offering a comprehensive range of options – from scleral to custom soft, ortho-K and now custom GP lenses.”
ASANA GP lenses are designed to maintain their shape throughout the day, delivering excellent visual acuity. Their rigid material resists protein and fatty deposits, helping to maintain clarity and comfort. Highly durable, they offer strong resistance to breaking and chipping, which can make them a cost-effective option due to less frequent replacement.1-3 For patients with high corneal astigmatism, severe refractive errors, keratoconus, corneal irregularities or post-surgical vision correction needs, gas permeable lenses provide enhanced visual precision to address these more complex vision challenges.1,2
“Rigid gas permeable corneal contact lenses are an excellent option for certain patients, and having access to consultants to assist with fittings is a critical component of success,” said James R. Hoffman, OD, FAAO, Orange Park Eye Center, Orange Park, Florida. “With ASANA, eye care professionals get both, along with fast manufacturing and shipping times, a generous warranty period and an extensive range of lens designs such as spherical, toric, multifocal and more. It’s an excellent option, particularly for busy practices.”
ASANA GP lenses are custom made exclusively with Boston® materials, and through the EZ-Exchange Warranty Program, unlimited lens remakes are available for 120 days.* For more information on ASANA GP lens portfolio, visit https://www.bauschsvp.com/lenses/asana/.
Important Safety Information for Gas Permeable and Customized Soft Contact Lenses
WARNINGS:
Patients should be advised of the following warnings pertaining to contact lens wear:
CONTRAINDICATIONS:
Do not use when any of the following conditions exist:
ADVERSE EFFECTS:
The following problems may occur with the use of contact lenses:
About Bausch + Lomb
Our mission is simple – we help people see better to live better, all over the world. For nearly two centuries we’ve evolved with the changing needs of patients and customers, and our commitment to innovation and improving the standard of care in eye health has never been stronger. From contact lenses to prescription products, over-the-counter options, surgical devices and more, we’re turning bold ideas into better outcomes through passion, perseverance and purpose. Learn more at www.bausch.com and connect with us on Facebook, Instagram, LinkedIn, X and YouTube.
*See bauschsvp.com/policies for details.
References
©2025 Bausch + Lomb.
MTB.0473.USA.25
Last Trade: | US$15.19 |
Daily Change: | -0.13 -0.85 |
Daily Volume: | 308,821 |
Market Cap: | US$5.380B |
September 11, 2025 September 09, 2025 August 18, 2025 July 30, 2025 July 29, 2025 |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load